Navigation Links
CRF announces late breaking trials and first report investigations to be presented at TCT 2013
Date:9/20/2013

NEW YORK, NY September 20, 2013 The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place October 28 November 1, 2013 at The Moscone Center in San Francisco, California.

Clinical trial data and first report investigations presented at TCT often direct the course of patient therapies. The studies selected will shed new light on the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent cardiovascular disease, one of the leading causes of death globally.

Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Tuesday, October 29; Wednesday, October 30; and Thursday, October 31.

This year, TCT will also mark 25 years of innovation with a day-long look back at the significant contributions that interventional cardiology has made to patients with cardiovascular disease, as well as an inspiring look ahead at new therapies being developed for the not too distant future.

Media are invited to attend TCT; press credentials and registration information can be found here: http://www.tctconference.com/press/press-registration-form.html

TUESDAY OCTOBER 29, 2013
Late Breaking Trials

  • SAFE-PCI: A Prospective, Registry-Based Randomized Trial of Radial Versus Femoral Vascular Access in Women Undergoing Diagnostic Cardiac Catheterization and PCI

  • COREVALVE EXTREME RISK: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Self-Expanding Transcatheter Heart Valve in Patients with Severe Aortic Stenosis

  • SORT-OUT VI: A Prospective, Randomized "All-Comers" Trial of Biodegradable Polymer-Coated Biolimus-Eluting Stents Versus Biocompatible Polymer-Coated Zotarolimus-Eluting Coronary Stents

WEDNESDAY, OCTOBER 30, 2013
Late Breaking Trials

  • EUROMAX: A Prospective, Randomized Trial of Ambulance Initiation of Bivalirudin Versus Heparin Glycoprotein IIb/IIIa Inhibitors in Patients with STEMI Undergoing Primary PCI

  • NORDIC-BALTIC BIFURCATION IV: A Prospective, Randomized Trial of a Two-Stent Strategy Versus a Provisional Stent Strategy in True Coronary Bifurcation Lesions

  • TRYTON: A Prospective, Randomized Trial of a Dedicated Sidebranch Stent Versus a Provisional Stent Strategy in True Coronary Bifurcation Lesions

First Report Investigations

  • LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel Coated Balloon Versus Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

  • RIBS V: A Prospective, Randomized Trial of Paclitaxel Coated Balloon Angioplasty Versus Everolimus-Eluting Stents in Bare Metal In-Stent Restenosis

  • SMART-CASE: A Prospective, Randomized Trial of Conservative Revascularization Versus Aggressive Revascularization in Patients with Intermediate Lesions Undergoing PCI with Angiographic Guidance Alone

  • HeartFlowNXT: A Prospective, Registry Evaluation of Noninvasive FFRCT Versus Invasive FFR

  • ADVISE II: A Prospective, Registry Evaluation of iFR Versus FFR CHILL-MI: A Prospective, Randomized Trial of Therapeutic Hypothermia in Patients with Acute Myocardial Infarction Undergoing Primary PCI

THURSDAY, OCTOBER 31, 2013
Late Breaking Trials

  • OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy After PCI

  • ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of 2 Years Versus 1 Year of Dual Antiplatelet Therapy After PCI

  • DUTCH PEERS (TWENTE II): A Prospective, Randomized "All-Comers" Trial of Zotarolimus-Eluting Stents Versus Everolimus-Eluting Coronary Stents

First Report Investigations

  • REPRISE II: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Repositionable Transcatheter Heart Valve in Patients with Severe Aortic Stenosis

  • FREEDOM: A Prospective, Randomized Trial of First Generation DES Versus CABG in Insulin and Non-Insulin Treated Diabetic Patients

  • HYBRID: A Prospective, Randomized Trial of Hybrid Coronary Revascularization Versus Standard Surgical Revascularization in Multivessel Disease

  • TRANSLATE-POPS: A Prospective, Cluster-Randomized Trial of Routine Platelet Function Testing in Patients Undergoing PCI

  • GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

  • TATORT-NSTEMI: A Prospective, Randomized Trial of Thrombus Aspiration in Thrombus Containing Culprit Lesions in Non-ST-Segment Elevation Myocardial Infarction


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. National Personal Training Institute Announces Two New Locations in Pittsburgh and New York City
2. Baron and Budd Announces Second Transvaginal Mesh Lawsuit Settlement for Bard
3. 360Websitedesign Announces Website Maintenance Services
4. ELK Consulting announces their new editing service
5. Zion Health Announces Native Remedy; Ancient Clay Soaps for Sensitive Skin; New Addition to Whole Foods Market Body Care in Andover, MA
6. Heroes in Recovery Announces Second Annual Race in Roswell, Georgia
7. Fitness 19 Announces the Opening of the Newbury Park, CA Location
8. CBT News Announces In-Depth Coverage of NADA Convention in New Orleans
9. HMP Communications Holdings, LLC Announces Launch of Interventional Oncology 360
10. The Art of Living TV Show Announces 2013 Telly Award Honors for DC’s Wine Country - Visit Loudoun Segment
11. Online USA Doctors Announces a New Online, Medical Record System That Improves Patient Health Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: